Descrizione
Guzzinati S, Toffolutti F, Francisci S, De Paoli A, Giudici F, De Angelis R, Demuru E, Botta L, Tavilla A, Gatta G, Capocaccia R, Zorzi M, Caldarella A, Bidoli E, Falcini F, Bruni R, Migliore E, Puppo A, Ferrante M, Gasparotti C, Gambino ML, Carrozzi G, Bianconi F, Musolino A, Cavallo R, Mazzucco W, Fusco M, Ballotari P, Sampietro G, Ferretti S, Mangone L, Mantovani W, Mian M, Cascone G, Manzoni F, Galasso R, Piras D, Pesce MT, Bella F, Seghini P, Fanetti AC, Pinna P, Serraino D, Rossi S, Dal Maso L; AIRTUM Working Group.
ESMO Open. 2024 Jul;9(7):103635. doi: 10.1016/j.esmoop.2024.103635. Epub 2024 Jul 23. PMID: 39043021; PMCID: PMC11321301.
Background
The number and projections of cancer survivors are necessary to meet the healthcare needs of patients, while data on cure prevalence, that is, the percentage of patients who will not die of cancer by time since diagnosis, are lacking.
Materials and methods
Data from Italian cancer registries (duration of registration ranged from 9 to 40 years, with a median of 22 years) covering 47% of the population were used to calculate the limited-duration prevalence, the complete prevalence in 2018, projections to 2030, and cure prevalence, by cancer type, sex, age, and time since diagnosis.
Results
A total of 3 347 809 people were alive in Italy in 2018 after a cancer diagnosis, corresponding to 5.6% of the resident population. They will increase by 1.5% per year to 4 012 376 in 2030, corresponding to 6.9% of the resident population, 7.6% of women and ∼22% after age 75 years. In 2030, more than one-half of all prevalent cases (2 million) will have been diagnosed by ≥10 years. Those with breast (1.05 million), prostate (0.56 million), or colorectal cancers (0.47 million) will be 52% of all prevalent patients. Cure prevalence was 86% for all patients alive in 2018 (87% for patients with breast cancer and 99% for patients with thyroid or testicular cancer), increasing with time since diagnosis to 93% for patients alive after 5 years and 96% after 10 years. Among patients who survived at least 5 years, the excess risk of death (1 − cure prevalence) was <5% for patients with most cancer types except for those with cancers of the breast (8.3%), lung (11.1%), kidney (13.2%), and bladder (15.5%).
Conclusions
Study findings encourage the implementation of evidence-based policies aimed at improving long-term clinical follow-up and rehabilitation of people living after cancer diagnosis throughout the course of the disease. Updated estimates of complete prevalence are important to enhance data-driven cancer control planning.
Pubmed: https://pubmed.ncbi.nlm.nih.gov/39043021/
